Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedNov 24, 2025
DataAggregated Company Financials
Companies63
  • 7D5.5%
  • 3M17.7%
  • 1Y3.8%
  • YTD6.6%

In the last week, the Life Sciences industry is up 5.5%, with Thermo Fisher Scientific up 3.4%. During this same period, the Nautilus Biotechnology underperformed, falling 5.8%. This takes the industry's 12 month performance to a gain of 3.8%. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 27 Nov 2025US$666.4bUS$145.6bUS$12.4b36.2x53.8x4.6x
Sat, 25 Oct 2025US$663.2bUS$145.3bUS$14.5b34.1x45.9x4.6x
Mon, 22 Sep 2025US$573.4bUS$144.3bUS$14.6b30.7x39.4x4x
Wed, 20 Aug 2025US$582.2bUS$144.2bUS$14.5b29.3x40.2x4x
Fri, 18 Jul 2025US$525.0bUS$142.9bUS$9.1b35.6x57.5x3.7x
Sun, 15 Jun 2025US$526.1bUS$142.9bUS$9.2b35.7x57.4x3.7x
Tue, 13 May 2025US$505.6bUS$142.7bUS$9.6b36x52.7x3.5x
Thu, 10 Apr 2025US$486.3bUS$142.5bUS$9.9b35.2x48.9x3.4x
Sat, 08 Mar 2025US$607.6bUS$143.1bUS$9.8b42.5x62.3x4.2x
Mon, 03 Feb 2025US$691.5bUS$143.0bUS$10.4b41.1x66.5x4.8x
Wed, 01 Jan 2025US$650.7bUS$142.4bUS$10.2b44.2x63.6x4.6x
Fri, 29 Nov 2024US$669.3bUS$142.4bUS$10.2b44.5x65.4x4.7x
Sun, 27 Oct 2024US$674.4bUS$142.0bUS$8.3b35.4x81.6x4.7x
Tue, 24 Sep 2024US$746.6bUS$141.8bUS$8.5b37.7x87.9x5.3x
Thu, 22 Aug 2024US$747.2bUS$141.9bUS$8.3b37.9x90.1x5.3x
Sat, 20 Jul 2024US$680.3bUS$141.2bUS$12.2b39.9x55.7x4.8x
Mon, 17 Jun 2024US$695.0bUS$141.3bUS$12.2b37.9x57.1x4.9x
Wed, 15 May 2024US$724.6bUS$141.5bUS$12.6b39.4x57.7x5.1x
Fri, 12 Apr 2024US$727.0bUS$142.0bUS$12.8b43x56.8x5.1x
Sun, 10 Mar 2024US$754.1bUS$142.1bUS$12.8b44.5x58.8x5.3x
Tue, 06 Feb 2024US$705.3bUS$141.9bUS$12.8b38.6x54.9x5x
Thu, 04 Jan 2024US$683.5bUS$153.8bUS$14.2b36x48.2x4.4x
Sat, 02 Dec 2023US$645.5bUS$153.8bUS$14.0b35.5x46.1x4.2x
Mon, 30 Oct 2023US$565.9bUS$153.8bUS$11.3b29.2x50.3x3.7x
Wed, 27 Sep 2023US$667.0bUS$154.6bUS$11.2b33.5x59.5x4.3x
Fri, 25 Aug 2023US$707.8bUS$154.6bUS$11.2b32.9x63.2x4.6x
Sun, 23 Jul 2023US$741.4bUS$155.5bUS$12.7b29.4x58.4x4.8x
Tue, 20 Jun 2023US$704.3bUS$152.4bUS$12.5b29.3x56.3x4.6x
Thu, 18 May 2023US$673.1bUS$152.4bUS$12.6b28.4x53.3x4.4x
Sat, 15 Apr 2023US$737.2bUS$154.6bUS$10.8b30.5x68.2x4.8x
Mon, 13 Mar 2023US$693.6bUS$154.5bUS$10.9b29.6x63.9x4.5x
Wed, 08 Feb 2023US$763.2bUS$155.6bUS$9.1b32x83.8x4.9x
Fri, 06 Jan 2023US$720.8bUS$155.1bUS$8.8b28.3x82.1x4.6x
Sun, 04 Dec 2022US$780.9bUS$155.1bUS$8.8b28.9x89x5x
Price to Earnings Ratio

89x


Total Market Cap: US$780.9bTotal Earnings: US$8.8bTotal Revenue: US$155.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.1x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 53.8x which is lower than its 3-year average PE of 61.1x.
  • The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 12% per year over the last three years.
  • Meanwhile revenues for these companies have declined 2.1% per year.
  • This means that less sales are being generated overall, but since cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.86%
Healthcare4.73%
Life Sciences5.50%
Clinical Research and Equipment5.50%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$593.253.4%
+US$7.3b		13.7%PE33.9x
DHR DanaherUS$228.462.7%
+US$4.3b		-4.3%PE46.1x
A Agilent TechnologiesUS$154.376.9%
+US$2.8b		11.7%PE33.5x
IQV IQVIA HoldingsUS$231.806.6%
+US$2.4b		15.1%PE30.8x
ICLR ICONUS$183.6515.6%
+US$1.9b		-13.7%PE23.4x

Latest News

A
US$154.37
Agilent Technologies
7D
6.9%
1Y
11.7%

Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
ICLR
US$183.65
ICON
7D
15.6%
1Y
-13.7%
TMO
US$593.25
Thermo Fisher Scientific
7D
3.4%
1Y
13.7%

TMO: Recent Product Approvals And Expanding End Markets Will Support Steady Performance

Thermo Fisher Scientific's average analyst price target has increased by a notable margin, as analysts cite robust third-quarter performance and continued strength in key end markets as reasons for their more optimistic outlook. Analyst Commentary Recent analyst activity has led to a series of price target revisions for Thermo Fisher Scientific, reflecting both confidence in the company’s fundamentals and acknowledgement of ongoing sector headwinds.
SEER
US$1.95
Seer
7D
-2.5%
1Y
-22.0%
IQV
US$231.80
IQVIA Holdings
7D
6.6%
1Y
15.1%

IQV: Earnings Reacceleration Will Drive Outperformance Into 2026

Analysts have lifted their price target on IQVIA Holdings slightly from $246.84 to $247.50. They cite improving earnings momentum, greater business stability, and continued sector resilience as key supporting factors.
DHR
US$228.46
Danaher
7D
2.7%
1Y
-4.3%

DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside

Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.
ILMN
US$129.81
Illumina
7D
8.1%
1Y
-10.1%
MTD
US$1,486.55
Mettler-Toledo International
7D
5.8%
1Y
19.6%

MTD: Share Repurchases And Acquisitions Will Drive Measured Gains Ahead

Analysts have raised their price target for Mettler-Toledo International from $1,343.36 to $1,492.64. This change reflects improved expectations for revenue growth and updated financial assumptions.
NAGE
US$6.89
Niagen Bioscience
7D
-0.1%
1Y
-9.8%

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Nov 15
RPID
US$4.14
Rapid Micro Biosystems
7D
-5.0%
1Y
318.1%

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 37% Jump Shows Its Popularity With Investors

Nov 14
Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 37% Jump Shows Its Popularity With Investors
WAT
US$407.14
Waters
7D
8.2%
1Y
5.3%
CSBR
US$6.50
Champions Oncology
7D
-5.1%
1Y
50.8%
NAUT
US$2.27
Nautilus Biotechnology
7D
-5.8%
1Y
-1.3%
BNBX
US$2.49
BNB Plus
7D
-7.4%
1Y
-97.9%
ATLN
US$2.27
Atlantic International
7D
-10.3%
1Y
-56.3%

Atlantic International's Position Is Risky, It Is Not An Opportunity

Aug 01